Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 1999 Dec;65(6):1771-6.
doi: 10.1086/302674.

Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2

J L Hopper, M A Jenkins
Comment

Modeling the probability that Ashkenazi Jewish women carry a founder mutation in BRCA1 or BRCA2

J L Hopper et al. Am J Hum Genet. 1999 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Estimated probability of carrying a founder mutation in BRCA1 or BRCA2 for Ashkenazi women. A and C, women who have had breast or ovarian cancer, as a function of age at diagnosis. B and D, women who have not had breast or ovarian cancer, as a function of age at testing. In A and B, family history is defined in terms of number of first-degree relatives with breast cancer; in C and D, family history is defined in terms of whether any first-degree relative had breast cancer at age <50 years (early diagnosis). (Note that because, in the data set, there were no women age <40 years who were both affected and who had more than one affected first-degree relative, a probability has not been assigned to that category.)
See this image and copyright information in PMC

Comment on

References

Electronic-Database Information

    1. Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/Omim (for BRCA1 [MIM 113705] and BRCA2 [MIM 600185])

References

    1. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, et al (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505–514 - PMC - PubMed
    1. Baker RJ, Nelder JA (1978) The GLIM system, release 3: generalized linear interactive modelling. Numerical Algorithms Group, Oxford
    1. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, et al (1997) BRCA1 mutation in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409–1415 - PubMed
    1. Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker, MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64:963–970 - PMC - PubMed
    1. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MRE, Easton DF,and the Australian Breast Cancer Family Study (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Cancer Epidemiol Biomarker Prevent 8:741–747 - PubMed

MeSH terms